Works by Beguelin, W.

Results: 5

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.
Published in:
Oncogene, 2015, v. 34, n. 26, p. 3413, doi. 10.1038/onc.2014.272
By:
- Cordo Russo, R I;
- Béguelin, W;
- Díaz Flaqué, M C;
- Proietti, C J;
- Venturutti, L;
- Galigniana, N;
- Tkach, M;
- Guzmán, P;
- Roa, J C;
- O'Brien, N A;
- Charreau, E H;
- Schillaci, R;
- Elizalde, P V
Publication type:
Article
Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.
Published in:
Oncogene, 2006, v. 25, n. 59, p. 7723, doi. 10.1038/sj.onc.1209757
By:
- Salatino, M.;
- Beguelin, W.;
- Peters, M. G.;
- Carnevale, R.;
- Proietti, C. J.;
- Galigniana, M. D.;
- Vedoy, C. G.;
- Schillaci, R.;
- Charreau, E. H.;
- Sogayar, M. C.;
- Elizalde, P. V.
Publication type:
Article
Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies.
Published in:
Hematological Oncology, 2023, v. 41, p. 280, doi. 10.1002/hon.3164_192
By:
- Serganova, I.;
- Bucktrout, R.;
- Isshiki, Y.;
- Sarapulov, A.;
- Santella, A.;
- Rodriguez, M.;
- Chakraborty, S.;
- Brunschvig, S.;
- Qualls, D.;
- Vardhana, S.;
- Lesokhin, A.;
- Melnick, A.;
- Beguelin, W.;
- Zappasodi, R.
Publication type:
Article
EZH2 INHIBITION ENHANCES CAR T ANTITUMOR EFFECT BY INDUCING LYMPHOMA IMMUNOGENICITY AND ENHANCING T CELL FUNCTION.
Published in:
Hematological Oncology, 2023, v. 41, p. 228, doi. 10.1002/hon.3163_149
By:
- Isshiki, Y.;
- Porazzi, P.;
- Melnick, A.;
- Ruella, M.;
- Béguelin, W.
Publication type:
Article
IL10 receptor is a novel therapeutic target in DLBCLs.
Published in:
Leukemia (08876924), 2015, v. 29, n. 8, p. 1684, doi. 10.1038/leu.2015.57
By:
- Béguelin, W;
- Sawh, S;
- Chambwe, N;
- Chan, F C;
- Jiang, Y;
- Choo, J-W;
- Scott, D W;
- Chalmers, A;
- Geng, H;
- Tsikitas, L;
- Tam, W;
- Bhagat, G;
- Gascoyne, R D;
- Shaknovich, R
Publication type:
Article

Works by Beguelin, W.

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.

Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation.

Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies.

EZH2 INHIBITION ENHANCES CAR T ANTITUMOR EFFECT BY INDUCING LYMPHOMA IMMUNOGENICITY AND ENHANCING T CELL FUNCTION.

IL10 receptor is a novel therapeutic target in DLBCLs.